Liquidia expands L606 license to Europe/Japan; gets nebulizer rights; $3.5M upfront, up to $157.75M milestones

Liquidia Corp

Expanded exclusive license to include Europe, Japan, and other key markets outside North America; $3.5M upfront payment.
Up to $157.75M in additional milestone payments: $7.75M development + $150M commercial sales milestones outside North America.
Obtained exclusive rights to Pharmosa's next-generation smart-technology nebulizers for use with L606.
L606 pivotal study in PH-ILD expected to start later this year; positive EMA scientific advice received.
Open-label safety study shows L606 tolerated up to 378 mcg twice daily; supports twice-daily dosing via breath-actuated nebulizer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.